BioSpace News Archive

Business

Petauri™ Elects William Fleming and James Robinson to Its Board of Directors

Petauri Health, a purpose-built pharmaceutical services platform, announced that two highly regarded healthcare executives, William Fleming and James Robinson, have been elected as members of the company’s Board of Directors.

December 6, 2023
·
4 min read
Business

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Alentis Therapeutics today announced that Rizwan Velji has been appointed Chief Business Officer (CBO).

December 6, 2023
·
2 min read
Genetown

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

GENFIT (Nasdaq and Euronext: GNFT) today announced the publication in the Journal of Hepatology2 of a paper on the performance of NIS2+™ as a screening tool for the enrollment of patients in Metabolic Dysfunction–Associated Steatohepatitis (MASH) clinical trials.

December 6, 2023
·
8 min read
BioCapital

First-Ever Psilocybin Clinical Trial for Treatment of Bipolar II Depression Conducted at Sheppard Pratt Reveals Promising Results

JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).

December 6, 2023
·
3 min read
Artificial Intelligence (AI) in Drug Discovery Market Projected to Reach USD 14,518.68 Million by 2032

The global artificial intelligence (AI) in drug discovery market size was estimated at USD 1,495.28 million in 2022 and is projected to reach around USD 14,518.68 million by 2032, growing at a CAGR of 20.08% between 2022 and 2032.

December 6, 2023
·
9 min read
FDA

Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma

First BLA for an engineered T-cell therapy for solid tumors submitted to U.S. Food and Drug Administration

December 6, 2023
·
5 min read
Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

Journey Medical Corporation today announced that the Company received the official meeting minutes from its pre-New Drug Application (“NDA”) meeting with the FDA for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) to treat rosacea in adults.

December 6, 2023
·
6 min read
Genetown

Curis Announces Three Presentations at ASH

Curis, Inc. today announced that the Company along with its collaborative partners will be presenting three posters at the upcoming 65th ASH Annual Meeting and Exposition (ASH 2025).

December 6, 2023
·
7 min read
Genetown

Alnylam to Webcast Virtual R&D Day - December 6, 2023

Alnylam Pharmaceuticals, Inc. announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET.

December 6, 2023
·
1 min read
Drug Development

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001.

December 6, 2023
·
8 min read